Filtered By:
Source: Dose Response
Condition: Diabetes
Drug: Actos
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Hormesis and Endothelial Progenitor Cells
Dose Response. 2022 Feb 23;20(1):15593258211068625. doi: 10.1177/15593258211068625. eCollection 2022 Jan-Mar.ABSTRACTHormetic-biphasic dose response relationships are reported herein for human endothelial progenitor cells involving estradiol, nicotine, the anti-diabetic agent pioglitazone, resveratrol, and progesterone. In general, these studies demonstrate the capacity of these agents to enhance EPC proliferation and angiogenesis functional applications, having a focus on repairing endothelial tissue damage due to acute injury (e.g., stroke), as well as damage from chronic conditions (e.g., atherosclerosis) and normal agi...
Source: Dose Response - February 28, 2022 Category: Drugs & Pharmacology Authors: Edward J Calabrese Source Type: research
